282 related articles for article (PubMed ID: 27203208)
1. Inhibitors of Rho kinase (ROCK) signaling revert the malignant phenotype of breast cancer cells in 3D context.
Matsubara M; Bissell MJ
Oncotarget; 2016 May; 7(22):31602-22. PubMed ID: 27203208
[TBL] [Abstract][Full Text] [Related]
2. Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells.
Sun K; Duan X; Cai H; Liu X; Yang Y; Li M; Zhang X; Wang J
Clin Exp Med; 2016 Feb; 16(1):37-47. PubMed ID: 25596714
[TBL] [Abstract][Full Text] [Related]
3. ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells.
Guerra FS; Oliveira RG; Fraga CAM; Mermelstein CDS; Fernandes PD
Sci Rep; 2017 Oct; 7(1):13723. PubMed ID: 29057980
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of RhoA/ROCK signaling pathway promotes the apoptosis of gastric cancer cells.
Xu XT; Song QB; Yao Y; Ruan P; Tao ZZ
Hepatogastroenterology; 2012; 59(120):2523-6. PubMed ID: 22584506
[TBL] [Abstract][Full Text] [Related]
5. ROCK isoforms differentially modulate cancer cell motility by mechanosensing the substrate stiffness.
Peng Y; Chen Z; Chen Y; Li S; Jiang Y; Yang H; Wu C; You F; Zheng C; Zhu J; Tan Y; Qin X; Liu Y
Acta Biomater; 2019 Apr; 88():86-101. PubMed ID: 30771534
[TBL] [Abstract][Full Text] [Related]
6. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.
Tilghman SL; Townley I; Zhong Q; Carriere PP; Zou J; Llopis SD; Preyan LC; Williams CC; Skripnikova E; Bratton MR; Zhang Q; Wang G
Mol Cell Proteomics; 2013 Sep; 12(9):2440-55. PubMed ID: 23704778
[TBL] [Abstract][Full Text] [Related]
7. Raf-1/CK2 and RhoA/ROCK signaling promote TNF-α-mediated endothelial apoptosis via regulating vimentin cytoskeleton.
Yang L; Tang L; Dai F; Meng G; Yin R; Xu X; Yao W
Toxicology; 2017 Aug; 389():74-84. PubMed ID: 28743511
[TBL] [Abstract][Full Text] [Related]
8. PRL-3 engages the focal adhesion pathway in triple-negative breast cancer cells to alter actin structure and substrate adhesion properties critical for cell migration and invasion.
Gari HH; DeGala GD; Ray R; Lucia MS; Lambert JR
Cancer Lett; 2016 Oct; 380(2):505-512. PubMed ID: 27452906
[TBL] [Abstract][Full Text] [Related]
9. Senescent stromal cells induce cancer cell migration via inhibition of RhoA/ROCK/myosin-based cell contractility.
Aifuwa I; Giri A; Longe N; Lee SH; An SS; Wirtz D
Oncotarget; 2015 Oct; 6(31):30516-31. PubMed ID: 26483365
[TBL] [Abstract][Full Text] [Related]
10. RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
Patel RA; Forinash KD; Pireddu R; Sun Y; Sun N; Martin MP; Schönbrunn E; Lawrence NJ; Sebti SM
Cancer Res; 2012 Oct; 72(19):5025-34. PubMed ID: 22846914
[TBL] [Abstract][Full Text] [Related]
11. Role of the Rho-ROCK (Rho-associated kinase) signaling pathway in the regulation of pancreatic beta-cell function.
Hammar E; Tomas A; Bosco D; Halban PA
Endocrinology; 2009 May; 150(5):2072-9. PubMed ID: 19106222
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities.
Patel RA; Liu Y; Wang B; Li R; Sebti SM
Oncogene; 2014 Jan; 33(5):550-5. PubMed ID: 23396364
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone.
Liu S; Goldstein RH; Scepansky EM; Rosenblatt M
Cancer Res; 2009 Nov; 69(22):8742-51. PubMed ID: 19887617
[TBL] [Abstract][Full Text] [Related]
14. MDA-9/Syntenin (SDCBP) modulates small GTPases RhoA and Cdc42 via transforming growth factor β1 to enhance epithelial-mesenchymal transition in breast cancer.
Menezes ME; Shen XN; Das SK; Emdad L; Sarkar D; Fisher PB
Oncotarget; 2016 Dec; 7(49):80175-80189. PubMed ID: 27863394
[TBL] [Abstract][Full Text] [Related]
15. RhoA/ROCK signaling regulates smooth muscle phenotypic modulation and vascular remodeling via the JNK pathway and vimentin cytoskeleton.
Tang L; Dai F; Liu Y; Yu X; Huang C; Wang Y; Yao W
Pharmacol Res; 2018 Jul; 133():201-212. PubMed ID: 29791873
[TBL] [Abstract][Full Text] [Related]
16. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of casein kinase 1δ in breast cancer.
Rosenberg LH; Lafitte M; Quereda V; Grant W; Chen W; Bibian M; Noguchi Y; Fallahi M; Yang C; Chang JC; Roush WR; Cleveland JL; Duckett DR
Sci Transl Med; 2015 Dec; 7(318):318ra202. PubMed ID: 26676609
[TBL] [Abstract][Full Text] [Related]
18. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.
Xia Y; Cai X; Fan J; Zhang L; Li Z; Ren J; Wu G; Zhu F
Anticancer Drugs; 2017 Jun; 28(5):514-521. PubMed ID: 28225457
[TBL] [Abstract][Full Text] [Related]
19. α-TEA inhibits the growth and motility of human colon cancer cells via targeting RhoA/ROCK signaling.
Yao J; Gao P; Xu Y; Li Z
Mol Med Rep; 2016 Sep; 14(3):2534-40. PubMed ID: 27432222
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells.
Umelo IA; Wever OD; Kronenberger P; Noor A; Teugels E; Chen G; Bracke M; Grève JD
Lung Cancer; 2015 Nov; 90(2):167-74. PubMed ID: 26342549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
